Isoproterenol-induced cardiac hypertrophy in rats is mediated in part by IGF-I, which is upregulated via AT1 receptor activation.
Answers are grounded in this paper and cite their sources.
AT1 blockade may attenuate IGF-I-driven hypertrophy in this rat model; hypothesis-generating with no clinical implications yet.
Increased levels of plasma catecholamine lead to cardiac hypertrophy via the alpha-, beta-adrenergic receptors, and partially, type 1 angiotensin II (AT1) receptor. However, it remains unclear whether other factors are involved in catecholamine-induced cardiac hypertrophy. We investigated the expression of insulin-like growth factor (IGF)-I in hearts of male Wistar rats infused with a beta-adrenergic agent, isoproterenol (ISO) (3 mg/kg/day), with or without an AT1-receptor antagonist, TCV-116 (10 mg/kg/day). Cardiac myocytes became hypertrophied 1 day after the beginning of ISO administration. ISO induced a biphasic increase of cardiac myocytes positive for IGF-I protein in the early and late phases of the study period, whereas IGF-I gene expression was upregulated only in the late phase by ISO. TCV- 116 abolished the upregulation of IGF-I gene and protein expression in the late phase in association with the regression of cardiac hypertrophy. These results suggest that ISO-induced cardiac hypertrophy is mediated, at least in part, by IGF-I, the expression of which is upregulated through the activation of AT1 receptor.
No takes yet. Share an insight, caveat, or question.
Suzuki et al. (1999) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: